PALISADE BIO, INC. (PALI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6963894026
PALISADE BIO, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -18.06 m USD |
| EBIT | -16.77 m USD |
| Net income | -16.78 m USD |
| Diluted EPS – continuing operations | -0.30 USD |
Full history since 2005, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PALISADE BIO, INC.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
More stocks
- INFINITY NATURAL RESOURCES, INC. (INR)
- WildBrain Ltd (WILD.TO)
- Petron Malaysia Refining Marketing (3042.KL)
- Cobre Ltd (CBE.AX)
- Ramaco Resources, Inc. (METCB)
- Rhinebeck Bancorp, Inc. (RBKB)
- Inventage Lab, Inc. (389470.KQ)
- FuboTV Inc. (FUBO)
- Hold-Key Electric Wire & Cable Co Ltd (1618.TW)
- Yeedex Electronic Corporation (7556.TWO)
- Electromed, Inc. (ELMD)
- Tolu Minerals Ltd (TOK.AX)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.